Press Release – New York, NY – May 11, 2023 – Sichenzia Ross Ference LLP announced today that it represented Lexaria Bioscience Corp., (NASDAQ: “LEXX”), a global innovator in drug delivery platforms, in a $2.0 million public offering. The offering consisted of 2,106,000 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at an offering price of $0.95 per unit. The warrants are immediately exercisable at a price of $0.95 per share and will expire five years from the date of issuance.
Maxim Group LLC acted as sole placement agent in connection with this offering.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Avital Perlman, Glenn Burlingame, associate Jesse Blue, and law clerk Anastasia Hayes.
